A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis

A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis

Background Factors beyond the Psoriasis Area and Severity Index (PASI) contribute to disease severity in psoriasis and potentially affect treatment responses. Objective This subset analysis of data from two phase 3 clinical studies assessed baseline parameters in patients with different degrees of p...

Full description

Bibliographic Details
Main Authors: Lynda Spelman, Diana Rubel, Alan Brnabic, Nicole Burkhardt, Elisabeth Riedl, Peter Foley
Format: Article
Language:English
Published: Taylor & Francis Group 2022-01-01
Series:Journal of Dermatological Treatment
Subjects:
il-17
pasi
ixekizumab
phase 3
psoriasis
uncover
Online Access:http://dx.doi.org/10.1080/09546634.2020.1752888

Internet

http://dx.doi.org/10.1080/09546634.2020.1752888

Similar Items